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Abstract
Resveratrol, a grape polyphenol, is thought to be a
cancer preventive, yet its effects on metastatic breast
cancer are relatively unknown. Since cancer cell inva-
sion is dependent on cell migration, the chemotactic
response of MDA-MB-231 metastatic human breast
cancer cells to resveratrol, estradiol (E2), or epidermal
growth factor (EGF) was investigated. Resveratrol
decreased while E2 and EGF increased directed cell
migration. Resveratrol may inhibit cell migration by
altering the cytoskeleton. Resveratrol induced a rapid
global array of filopodia and decreased focal adhe-
sions and focal adhesion kinase (FAK) activity. E2 or
EGF treatment did not affect filopodia extension but
increased lamellipodia and associated focal adhesions
that are integral for cell migration. Combined resvera-
trol and E2 treatment resulted in a filopodia and focal
adhesion response similar to resveratrol alone. Com-
bined resveratrol and EGF resulted in a lamellipodia
and focal adhesion response similar to EGF alone. E2
and to a lesser extent resveratrol increased EGFR
activity. The cytoskeletal changes and EGFR activity in
response to E2 were blocked by EGFR1 inhibitor indi-
cating that E2 may increase cell migration via crosstalk
with EGFR signaling. These data suggest a promo-
tional role for E2 in breast cancer cell migration but an
antiestrogenic, preventative role for resveratrol.
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Keywords: Resveratrol, estradiol, filopodia, focal adhesions, cell migration.
Introduction
Estrogen (E2) acts by regulating gene transcription through
two major intracellular estrogen receptors (ERs), ERa and
ERb, to play a critical role in the establishment and main-
tenance of female reproductive function as well as in the
initiation and progression of breast and gynecologic can-
cers [1,2]. Consequently, inhibition of ERa has become a
major strategy for the prevention and treatment of breast
cancer [3]. However, this approach is limited to the treat-
ment of metastatic breast cancer because ERa expression
is often lost during breast cancer progression to the meta-
static state [4]. These ERa() cancers may still retain the more
recently identified ERb as well as membrane-bound forms of
ER, and more studies are necessary to understand the role of
these ER isoforms in breast cancer malignancy. In addition to
the well-established long-term (genomic) effects of E2 on gene
transcription [5], E2 also induces short-term (nongenomic)
effects. Such nonclassic effects of E2 have been reported from
a variety of cell types including breast cancer cells and are
thought to be modulated by plasmamembrane ERs that can
cross-activate a variety of signaling cascades [6,7].
Recent reports on the rapid, nongenomic action of E2 from a
variety of cell types and tissues have demonstrated novel roles
for E2 in the regulation of a variety of cell functions relevant to
cancer progression [8–11]. E2 cross-activates heterotrimeric G
proteins to stimulate adenylate cyclase and phospholipase C,
thus inducing protein kinase A (PKA), protein kinase C (PKC),
and intracellular Ca2+ fluxes [12,13]. Moreover, E2-bound ERa
has been shown to associate with Src tyrosine kinase as well
as the regulatory subunit of phosphoinositide 3-kinase (PI3-K)
to regulate signaling pathways implicated in cell proliferation,
survival, and migration [14,15]. Activation of membrane ERs by
E2 has been shown to transactivate epidermal growth factor
receptors (EGFRs) potentially through a G protein–coupled
pathway [11,16]. EGFRs are tyrosine kinase–type integral
membrane receptors that regulate signaling relevant to both
genomic effects on cell proliferation and survival as well as
nongenomic signaling to affect migration and invasion [17,18].
Interestingly, loss of ERa in breast cancer is associated with
overexpression of EGFRs that contribute to tumor malignancy
and poor prognosis [19]. Therefore, there is a pressing need to
investigate the nongenomic aspects of E2 signaling and how
it relates to metastatic breast cancer.
Abbreviations: E2, 17h-estradiol; EGF, epidermal growth factor; ER, estrogen receptor; FAK,
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Phytoestrogens are naturally occurring estrogen-like
plant compounds that act as agonists or antagonists of
E2 and may have protective action against some can-
cers as well as prevent the undesirable symptoms of
menopause [20]. Resveratrol (trans-3,4V,5 trihydroxystil-
bene), a phytoestrogen present in grape skin and red wine,
is known to have cancer-preventive and cardioprotective
properties [21,22]. Resveratrol binds to and activates
ERs (a and b) to exert both estrogenic and antiestrogenic
effects [23,24]. Resveratrol acts as a cancer-preventive
agent due to its antioxidant, proapoptotic, and antigrowth
properties [21,25,26]. Resveratrol may also be important
for breast cancer prevention because it inhibits breast
cancer cell growth in ERa(+) and ERa() cells [23,27,28].
We have previously demonstrated that in ER(+) breast
cancer cells, resveratrol reduces the activity of Akt, a regu-
lator of cell survival, and increases Akt activity in ERa()
ERb(+) breast cancer cells [29]. A recent report demon-
strated that resveratrol could directly inhibit Akt activity
of ER(+) breast cancer cells through an ERa-associated
PI3-K pathway [30].
Resveratrol has also been shown to prevent angio-
genesis and wound healing of endothelial cells, and such
antiangiogenic properties of resveratrol make it a good
candidate for the prevention of cancer progression [31–34].
Resveratrol has been demonstrated to reduce hepatoma
cell invasion in response to hepatocyte growth factor in vitro
and hepatoma and Lewis lung carcinoma invasion in mice
[31,35]. Resveratrol was recently shown to inhibit phorbol
myristate acetate– induced cervical cancer cell invasion [36].
Although the role of resveratrol in the inhibition of cancer
cell growth is well established, the role and mechanisms by
which resveratrol may act to prevent cancer metastasis re-
main to be investigated.
Directed cell migration is an integral component of cancer
cell invasion during metastasis. Metastatic cancer cells
break cell–cell adhesions and initiate movement out of the
primary tumor into surrounding tissues and blood vessels
[37]. Cancer cell invasion is regulated by growth factors that
can rapidly activate cell surface receptors to induce actin
polymerization and reorganization into actin-based exten-
sions such as filopodia (thin needle–shaped structures with
parallel actin bundles) and lamellipodia (flat cell surface
protrusions with cross-linked actin). Extension of lamellipo-
dia and dynamic turnover of focal adhesions at the leading
edge are thought to drive forward migration [37–40]. Filopo-
dia are not essential for cell migration and are considered
to function as environmental sensors [39].
Focal adhesions are multimolecular complexes formed by
the interaction of integrin receptors with the extracellular ma-
trix (ECM). Focal adhesions contain both structural and sig-
naling components with numerous tyrosine-phosphorylated
proteins such as focal adhesion kinase (FAK) and Src as well
as actin-binding proteins that anchor focal adhesions to the
actin cytoskeleton. FAK is recruited to the membrane in
response to integrin as well as growth factor receptor activa-
tion. FAK is activated by autophosphorylation atmultiple sites
that in turn interact with adapter and structural proteins
facilitating the modulation of cell proliferation, survival, mi-
gration, and cancer cell invasion [41].
Although ERa is commonly lost in metastatic breast
cancer [4], these cells still retain the ERb isoform, which
has been shown to interact with resveratrol [42]. Therefore,
as a first step toward investigating a role for resveratrol in
breast cancer metastasis, we monitored directed cell migra-
tion and accompanying changes in the cytoskeleton in
response to resveratrol or E2 in the ERa() ERb(+) MDA-
MB-231 [43] human metastatic breast cancer cell line. For
the first time, the present data demonstrate that resveratrol
may inhibit breast cancer cell migration by modulating the
actin cytoskeleton to form a global array of filopodia and by
decreasing focal adhesion assembly and FAK activity. Con-
versely, E2 increases cell migration and accompanying
lamellipodia extension and focal adhesion assembly. Thus,
these data indicate that resveratrol may prevent, whereas
E2 may advance, metastatic breast cancer in ERa()
ERb(+) tumors.
Materials and Methods
Reagents
All culture media components were from Life Technolo-
gies/Gibco (Rockville, MD). EGF was obtained from Upstate
Biotechnology, Inc. (Charlottesville, VA). 17b-Estradiol (E2)
was obtained from Sigma (St. Louis, MO). trans-Resveratrol
was from LKT Laboratories (St. Paul, MN). All chemo-
attractants were dissolved in DMSO. Rhodamine phalloidin
was purchased from Molecular Probes (Eugene, OR). Anti-
phosphotyrosine and anti-ERa antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-ERb, anti-EGFR,
and anti-phosphoEGFR antibodies were from Upstate Bio-
technology, Inc. FITC-conjugated goat antimouse antibody
was from Cappel (West Chester, PA). Tyrphostin AG1478
was purchased from Calbiochem (San Diego, CA).
Cell Culture
Human breast cancer cell lines were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS) at 37jC in 5% CO2.
Migration Assay
Migration assays were conducted according to Ref. [44].
MDA-MB-231 cells were serum-starved in phenol red–free
DMEM for 24 hours. Cells were then trypsinized, recovered
with trypsin inhibitor (0.5 mg/ml), and seeded at 1  105 cells
per chamber in the upper well of Costar wells (VWR,
Suwanee, GA) containing membranes with 8-mm–diameter
pores. DMSO (control), E2 (0.1 mM), EGF (50 ng/ml), or
resveratrol (50 mM) was added as a chemoattractant to the
bottom wells for 8 hours. For experiments where the effect
of resveratrol was analyzed in combination with E2 or EGF,
resveratrol was added to the bottom well for 10 minutes
followed by E2 or EGF for the duration of the experiment.
Cells on the upper surface of the membrane were removed,
and cells that had moved through to the other side of the
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membrane were stained with propidium iodide and quanti-
fied. For statistical purposes, the total number of cells
migrated in 10 microscopic fields per well were counted for
at least three separate experiments.
Immunofluorescence Microscopy
Cells were seeded at 1.5  105 cells per cover slip and
grown overnight in DMEM in six-well plates. Cells were
serum-starved in phenol red–free DMEM for 24 hours. Cells
were then treated for 10 minutes with DMSO (control), E2
(0.1 mM), EGF (50 ng/ml), or resveratrol (10, 50, or 100 mM).
For experiments where the effect of resveratrol was ana-
lyzed in combination with E2 or EGF, cells were preincubated
in resveratrol for 10 minutes and incubated with E2 or EGF
for a further 10 minutes. For experiments using tyrphostin
AG1478 to inhibit EGFR activity, cells were preincubated in
50 mM tyrphostin AG1478 for 15 minutes as described in
Ref. [15]. Cells were fixed with 3.7% formaldehyde in PBS
for 15 minutes, permeabilized with 0.2% Triton X-100 for
20 minutes, and blocked with 5% bovine serum albumin
(BSA). Cells were then probed with rhodamine phalloidin to
visualize F-actin and anti-phosphotyrosine followed by FITC-
conjugated secondary antibody to visualize focal adhesions,
as described in Ref. [45]. Micrographs at 600 magnifica-
tion were digitally captured using a SpotII digital camera
and software (Diagnostic Instruments, Inc., Sterling Heights,
MI). Cells in 10 microscopic fields per treatment were
counted for three separate experiments.
Analysis of ER Expression and FAK and EGFR Activity
Cells were disrupted in lysis buffer [20 mM Tris–HCl (pH
7.5), 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 2.5 mM
sodium pyrophosphate, 50 mM sodium fluoride, 10% glyc-
erol, 1%NP-40, 1mMDTT, 0.5% deoxycholate, and protease
inhibitors] on ice. Lysates were centrifuged at 14,000 rpm,
and the supernatant mixed with Laemmli sample buffer,
equally loaded, and separated on 10% SDS-PAGE gels.
Proteins were transferred to PVDFmembranes, blocked with
5% BSA, and probed with specific primary antibodies. Posi-
tive bands were detected using a horseradish peroxidase
(HRP)–conjugated secondary antibody and developed with
Super Signal West Fempto Substrate (Pierce Biotechnology,
Rockford, IL). For analysis of ER isoform or EGFR expres-
sion, cell lysates containing equal amounts of protein, as
determined by total protein assays (Bio-Rad, Hercules, CA),
were loaded and specific ER isoforms detected using mono-
clonal antibodies to ERa, ERb, EGFR, or phosphoEGFR.
For analysis of FAK activity, anti-FAK (against the N-
terminus) and anti-phosphoFAK (Tyr-397) antibodies were
used as probes. The densities of positive bands were
quantified using Scion Image software. The relative FAK
activity was calculated as the ratio of the density of phos-
phoFAK in stimulated cell lysates to the density of FAK in
stimulated cell lysates divided by the ratio of the density of
phosphoFAK in unstimulated cell lysates to the density of
FAK in unstimulated cell lysates, as described in Ref. [29]. In
our previously published results, FAK activity was quantified
using a C-terminal anti-FAK antibody to detect total FAK
levels. Herein, this assay has been improved by the use of
a total anti-FAK antibody that detects the N-terminus of
FAK, thus including all of the proteins detected by an anti-
phosphoFAK tyr-397 antibody. The results are representa-
tive of three separate experiments.
For the analysis of EGFR activity, cells were pre-
treated with tyrphostin AG1478 (50 mM) for 15 minutes as
described in Ref. [15]. Cells were then treated with 50 ng/ml
EGF or vehicle for 10 minutes, lysed, and Western-blotted
as described above using an antibody against phospho-
EGFR (Y1173).
Statistical Analysis
Data are expressed as mean ± S.E.M. P values were
calculated from unpaired t-tests using Microsoft Excel and
considered significant at values less than .05.
Results
To determine the effect of resveratrol on cell functions
relevant to cancer cell invasion, we investigated the
changes in cell migration, cell surface actin structures, focal
adhesion assembly, and FAK and EGFR activity induced
by 10-minute exposure to resveratrol (50 mM) compared
to DMSO (control), E2 (0.1 mM), or EGF (50 ng/ml). The
concentration of resveratrol used is comparable to the range
of concentrations used to demonstrate interactions with ER
[24] and signal transduction through modulation of gene
expression [36]. The concentration for resveratrol used is
well within the published range for resveratrol action, where
different cell types, including breast cancer cells, were
incubated in concentrations of resveratrol ranging from 1 to
100 mM for over 24 hours [30,34,46–48]. E2 concentration
is in the range used for the demonstration of nongenomic
effects in breast cancer cells [15,49]. The concentration
of EGF is in the range used to activate EGFR and elicit ef-
fects on the actin cytoskeleton and invasion of breast cancer
cells [50,51].
Resveratrol Decreases Migration Whereas E2 Increases
Migration of MDA-MB-231 Cells
As shown in Figure 1, the role of E2 and resveratrol as
chemoattractants in directed cell migration was analyzed in
ERa() b(+) MDA-MB-231 metastatic human breast cancer
cells. E2 and EGF treatments both significantly increased
cell migration by 50% and 30%, respectively, compared
to control. Resveratrol treatment resulted in significantly
decreased cell migration by 26% compared to control. To
investigate the ability of resveratrol to inhibit E2 or EGF
action, cells were treated with resveratrol prior to E2 (Res/
E2) or EGF (Res/EGF). Combined treatment of Res/E2 or
Res/EGF was significantly decreased from unstimulated
control by 33% and 41%, respectively, but were not signifi-
cantly different from resveratrol-treated cells alone. In Res/
E2 treatments, the number of cells that migrated was signifi-
cantly reduced by 55% when compared to E2 alone. In Res/
EGF treatments, the number of cells that migrated was also
significantly reduced by 55% when compared to EGF alone.
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Thus, resveratrol effectively inhibited cell migration even
in the presence of E2 or EGF, both stimulators of directed
cell migration.
Resveratrol, But Not E2, Induces Filopodia Extension in
ER(+) Breast Cancer Cells
To investigate a structural mechanism for the migratory
response of ERa() b(+) MDA-MB-231 to resveratrol and
E2, we monitored the effect of these compounds on the actin
cytoskeleton of ERa(+) T47D, ERa() b(+) MDA-MB-231,
and ERa() b() SKBR3 human breast cancer cell lines.
The ER a and b protein expression status of all three cell
lines was confirmed by Western blot analysis with monospe-
cific antibodies (Figure 2B). As shown in Figure 2A, addition
of resveratrol or E2 to quiescent T47D and MDA-MB-231
human breast cancer cell lines resulted in rapid reorganiza-
tion of the actin cytoskeleton. However, the actin cytoskeletal
response to resveratrol compared to E2 was structurally very
different. Treatment with resveratrol resulted in a dynamic
global extension of filopodia, which contain bundles of actin
filaments; whereas treatment with E2 resulted in extension
of lamellipodia, which contain cross-linked networks of actin
filaments. In the ERa() b(+) MDA-MB-231 cells, we have
observed significant increases in filopodia extension from
5 to 30 minutes following resveratrol treatment at concen-
trations ranging from 10 to 100 mM with saturation at 50 mM
resveratrol (data not shown). Resveratrol-induced increases
in filopodia were also observed for the ERab(+) T47D cells
(Figure 2A). However, E2 or resveratrol did not affect the
actin cytoskeleton of the ERab() metastatic breast cancer
cell line, SKBR3 (Figure 2A). As confirmed in Figure 2B,
the SKBR3 cell line is known to be deficient in ER mRNA
expression [52]. Therefore, these effects of E2 and resvera-
trol on the actin cytoskeleton may be ER-dependent but not
specific to ERa.
Because we investigate a role for E2 and resveratrol in
crosstalk with EGFR signaling, expression of EGFR was
also confirmed in these breast cancer cell lines (Figure 2B).
Although the EGFR antibody was not sensitive enough to
detect the low expression of EGFR in T47D cells, Western
blot analysis of lysates from cells grown in serum with
a phospho-specific EGFR antibody detected activated
EGFR in T47D cells as well as in MDA-MB-231 and SKBR3
cells. Therefore, the observed lack of an actin cytoskeletal
response following E2 or resveratrol in SKBR3 cells is not
due to lack of EGFR function but probably due to their
ER() status.
Stimulation of ERa() b(+) MDA-MB-231 cells with EGF
resulted in lamellipodia formation, as has been reported in
other breast cancer cell lines [37]. Interestingly, E2 exerted a
similar, but not as pronounced, effect as EGF by inducing
lamellipodia. This has previously been shown in ERab(+)
MCF-7 breast cancer cells [38]. The number of filopodia
extended in cells treated with E2 or EGF did not differ
significantly from controls (Figures 2–4). These parallel
cytoskeletal responses to E2 or EGF suggest that E2 may
exert effects on the actin cytoskeleton through EGFR.
As shown in Figure 3, the number of filopodia extended in
response to 50 mM resveratrol was significantly increased by
f4.5-fold compared to control, E2, or EGF. To evaluate the
role of resveratrol as an inhibitor of E2 or EGF action on the
cytoskeleton, the number of filopodia was quantified in cells
preincubated with resveratrol and subsequently stimulated
Figure 1. Effects of E2, EGF, and trans-resveratrol on directed cell migration of MDA-MB-231 cells. Cells were serum-starved in phenol red– free media for
24 hours and migration assays were conducted using the following as chemoattractants for 8 hours: DMSO as control (Un); 0.1 M E2 (E2); 50 ng/ml EGF (EGF);
50 M resveratrol (Res), pretreated with Res for 10 minutes followed by E2 for 10 minutes (Res/E2), or pretreated with Res for 10 minutes followed by EGF for
10 minutes (Res/EGF). The number of cells that migrated through the upper chamber of Costar wells was quantified and made relative to DMSO control. Data are
expressed as mean cells migrated ± SEM of at least three independent experiments. Treatments denoted by the same letter indicate no significant difference
between those treatments. Treatments denoted by different letters indicate a significant difference between those treatments at P < .05.
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Figure 2. Effect of E2 and trans-resveratrol on the actin cytoskeleton of ER (+) and () cells. (A) Micrographs of T47D, MDA-MB-231, and SKBR3 cells at 600
magnification. Cells were serum-starved in phenol red– free media for 24 hours and stimulated for 10 minutes with DMSO as control (Un), E2 (0.1 M), or 50 M
resveratrol (Res). Cells were stained with rhodamine phalloidin to visualize F-actin. Arrowheads (<) indicate a filopodium. (B) Western blot of whole cell lysates of
T47D, MDA-MB-231, and SKBR3. Equal amounts of proteins from cell lysates were loaded on SDS-PAGE and Western-blotted using anti-ERa (65 kDa band) or
anti-ER (53 kDa band). Equal amounts of cell lysates were also probed with anti-EGFR1 (185 kDa) or anti-phosphoEGFR (Y1173) (185 kDa).
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Figure 3. Effect of E2, EGF, or trans-resveratrol on the actin cytoskeleton of MDA-MB-231 cells. Cells were serum-starved in phenol red– free media for 24 hours
and stimulated for 10 minutes with DMSO as control (Un); 0.1 M E2 (E2); 50 ng/ml EGF (EGF); and 50 M resveratrol (Res), pretreated with Res for 10 minutes
followed by E2 for 10 minutes (Res/E2), or pretreated with Res for 10 minutes followed by EGF for 10 minutes (Res/EGF). Cells were stained with rhodamine
phalloidin to visualize F-actin. (A) Micrographs at 600 magnification. Arrowheads (<) indicate a filopodium; arrows (p) indicate a lamellipodium. (B) Filopodia
number was quantified for at least 10 microscopic fields per treatment per experiment and made relative to DMSO control (Un). Data expressed as mean filopodia ±
SEM of three independent experiments. Treatments denoted by the same letter indicate no significant difference between those treatments. Treatments denoted
by different letters indicate a significant difference between those treatments at P < .05.
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with E2 (Res/E2) or EGF (Res/EGF). In Res/E2 treatments,
the number of filopodia was significantly greater than unsti-
mulated control or E2 alone by f3-fold. However, the
number of filopodia extended in this Res/E2 combined treat-
ment was still significantly less (31%) when compared to
resveratrol alone. Resveratrol pretreatment followed by EGF
(Res/EGF) did not significantly increase filopodia number
when compared to EGF alone. Thus, these results demon-
strate that resveratrol may counteract the effect of E2 on the
actin cytoskeleton. In the presence of EGF, resveratrol did
not affect direct EGF signaling to the actin cytoskeleton, indi-
cating that resveratrol may not directly compete with EGF to
alter EGFR signaling.
Resveratrol and E2 Effects on the Actin Cytoskeleton of
MDA-MB-231 Cells Are Modulated by EGFR Inhibitor
Plasmamembrane ERs have been implicated in the
cross-activation of tyrosine kinase-type growth factor recep-
tors, such as EGFR [7,11]. To further evaluate the role of
EGFR on resveratrol-mediated effects on the actin cytoskele-
ton, we investigated the effect of tyrphostin AG1478, an
EGFR1 specific inhibitor. As shown in Figure 4A, treatment
of unstimulated cells with AG1478 (Un+) resulted in a signifi-
cant increase in the number of filopodia when compared to
unstimulated control (Un). This increase may be due to a
nonspecific effect of AG1478 treatment or inhibition of intrin-
sic EGFR activity.
Figure 4. Effect of tyrphostin AG1478 on filopodia formation in MDA-MB-231 cells. (A) Cells were serum-starved in phenol red– free media for 24 hours and
pretreated with vehicle (AG1478) or tyrphostin AG1478 (+AG1478) for 15 minutes then treated with DMSO as control (Un), 0.1 M E2 (E2), 50 ng/ml EGF (EGF),
or 50 M resveratrol (Res) for 10 minutes. Cells were stained with rhodamine phalloidin to visualize F-actin. Filopodia number was quantified for at least
10 microscopic fields per treatment per experiment and made relative to DMSO control (Un). Data expressed as mean filopodia ± SEM of three independent
experiments. Treatments denoted by the same letter indicate no significant difference between those treatments. Treatments denoted by different letters indicate
a significant difference between those treatments at P < .05. (B) Quiescent cells were pretreated with DMSO (AG1478) or tyrphostin AG1478 (+AG1478) for
15 minutes then treated with DMSO as control (Un), 0.1 M E2 (E2), 50 ng/ml EGF (EGF), or 50 M resveratrol (Res) for 10 minutes. Cells were immediately lysed
and equal amounts of protein were separated on SDS-PAGE and Western-blotted for activated EGFR using an anti-phosphoEGFR (Y1173) antibody. The result is
representative of two separate experiments.
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When E2- or EGF-treated cells were pretreated with AG1478
(E2
+ or EGF+, respectively), the filopodia number increased
significantly compared to unstimulated plus AG1478 (Un+)
treatment. There was a significant f2-fold increase of
filopodia in cells treated with E2 in the presence of AG1478
(E2
+) compared to those treated with E2 in the absence of
AG1478 (E2
), or in cells treated with EGF in the presence of
AG1478 (EGF+) compared to those treated with EGF in the
absence of AG1478 (EGF). These increases may also be a
direct result of inhibition of EGFR activity or a nonspecific
effect of AG1478.
Conversely, AG1478 treatment partially reduced the
number of filopodia extended in response to resveratrol
(Res+) by f1.4-fold when compared to resveratrol alone
(Res). The number of filopodia in resveratrol-treated cells in
the presence of AG1478 (Res+) was still significantly higher
than the number of filopodia in unstimulated cells in the
presence of AG1478 (Un+) (f2-fold) and in E2-stimulated
cells in the presence of AG1478 (E2
+) (27%), and nearly
significant for EGF-stimulated cells in the presence of
AG1478 (EGF+) (24%; P = .06). Thus, EGFR signaling
appears to play a partial role in resveratrol signaling to the
actin cytoskeleton.
To determine the effect of E2 or resveratrol on EGFR
activation, EGFR activity was detected by a monospecific
antibody to the phosphotyrosine residue 1173 of EGFR,
which is autophosphorylated upon receptor occupation.
Our results are limited by the sensitivity of the phosphoEGFR
(Y1173) antibody and by the fact that EGFR is phosphoryl-
ated on several other phosphotyrosine residues upon acti-
vation [19]. As shown in Figure 4B, there was a very low
intrinsic EGFR activity in quiescent MDA-MB-231 cells. As
expected, EGF stimulation resulted in a marked increase in
phosphoEGFR levels, which was abolished by AG1478
treatment. Similarly, E2 induced EGFR activity, but to a
lesser degree than EGF, and was inhibited by AG1478.
Interestingly, resveratrol also increased EGFR activity
but to a lesser degree than E2. This activity did not appear
to be attenuated by AG1478. These results reveal a po-
tential resveratrol-induced AG1478-insensitive fraction of
EGFR signaling.
Resveratrol Decreases, Whereas E2 Increases, Focal
Adhesion Number in MDA-MB-231 Cells
Because focal adhesions are commonly associated with
cell surface actin structures such as filopodia and lamellipo-
dia [38], cells stimulated with E2, EGF, or resveratrol were
examined for focal adhesions. As shown in Figure 5b, EGF
increased the number of focal adhesions per cell compared
to unstimulated controls in a statistically significant manner
byf2-fold. Increased focal adhesion assembly in response
to E2 was more moderate at 20% but still statistically signifi-
cant when compared to controls, again demonstrating a
similar but not as pronounced effect on the cytoskeleton as
EGF. Moreover, the focal adhesions extended in response to
E2 or EGF were observed to be smaller and distributed in
lamellipodia, and thus characteristic of motile cells.
Resveratrol treatment resulted in significantly reduced
focal adhesion assembly by 36% compared to control
(Figure 5). Resveratrol-induced filopodia did not appear to
be associated with focal adhesions. To investigate the ability
of resveratrol to inhibit E2 or EGF action, focal adhesion
number was quantitated in E2- or EGF-treated cells after
resveratrol treatment. When cells were treated with resvera-
trol prior to E2 (Res/E2), focal adhesions per cell were
significantly reduced by 29% when compared to E2 alone.
There was also a 29% reduction in focal adhesion number
observed for cells treated with resveratrol prior to EGF (Res/
EGF) when compared to EGF alone (P = .07). However,
focal adhesions in Res/E2 and Res/EGF treatments were
still significantly higher than resveratrol alone by f1.6- and
f2.8-fold, respectively. These results indicate at least a
partial role for ER in resveratrol-mediated inhibition of focal
complex assembly.
As shown in Figure 6, AG1478 treatment did not signifi-
cantly alter the amount of focal adhesions in unstimulated
cells. Compared to E2 alone (E2
), treatment with AG1478
(E2
+) reduced the number of focal adhesions significantly by
41%. The number of focal adhesions per cell in response to
EGF (EGF) also decreased significantly in the presence of
tyrphostin AG1478 (EGF+) by 56%. The decrease in focal
adhesion number in the presence of AG1478 in E2-treated
(E2
+) or EGF-treated (EGF+) cells was significantly lower than
that of unstimulated cells in the presence of AG1478 (Un+) by
13% and 9%, respectively. We did not observe a significant
reduction in focal adhesion number in the presence of ty-
rphostin AG1478 (Res+) in resveratrol-treated cells (Res).
This result demonstrates that the increased focal adhe-
sions in both E2- and EGF-treated cells are probably due to
EGFR activity.
Resveratrol Decreases FAK Activity in MDA-MB-231 Cells
Because FAK is a signaling intermediate that is recruited
to focal adhesions immediately following integrin activation
and is also regulated by growth factor receptor stimulation,
we determined FAK activity in response to resveratrol. FAK
activity in response to resveratrol was determined by anal-
ysis of autophosphorylation of FAK following a range of
resveratrol concentrations as described in Ref. [29]. In
MDA-MB-231 cells, resveratrol at 10 minutes slightly in-
creased FAK activity at 1 and 10 mM. Endogenous FAK
activity decreased when treated with 25 mM resveratrol by
34%, at 50 mM by 52%, and at 100 mM by 84% (Figure 7).
Thus, the decreased FAK activity in response to resveratrol
corresponds to the decreased focal adhesion assembly
by resveratrol.
Discussion
Overall, the data presented demonstrate that although E2
and EGF increase directed cell migration, lamellipodia ex-
tension, and focal adhesion assembly, resveratrol exerts an
opposite effect by inhibiting cell migration, increasing filopo-
dia formation, and decreasing the number of focal adhesions
and FAK activity. Thus, rapid resveratrol signaling to the
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Figure 5. Effect of E2, EGF, or trans-resveratrol on focal adhesion assembly in MDA-MB-231 cells. Cells were serum-starved in phenol red– free media for 24 hours
and stimulated for 10 minutes with DMSO as control (Un); 0.1 M E2 (E2); 50 ng/ml EGF (EGF); 50 M resveratrol (Res), pretreated with Res for 10 minutes
followed by E2 for 10 minutes (Res/E2), or pretreated with Res for 10 minutes followed by EGF for 10 minutes (Res/EGF). Cells were probed with anti-
phosphotyrosine primary antibody and FITC-conjugated secondary antibody to visualize focal adhesions. (a) Micrographs at 600 magnification. (b) Focal
adhesion number per cell was quantified for at least 10 microscopic fields per treatment per experiment and made relative to DMSO control (Un). Data expressed
as mean focal adhesions ± SEM of three independent experiments. Treatments denoted by the same letter indicate no significant difference between those
treatments. Treatments denoted by different letters indicate a significant difference between those treatments at P < .05.
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cytoskeleton of ERa() ER b(+) MDA-MB-231 breast cancer
cells appears to function in an antiestrogenic manner.
Cell migration is crucial for cancer cell invasion and
metastasis. Herein, we report that resveratrol inhibits cell
migration, whereas E2 acts similar to EGF, a known promoter
of cell migration. This resveratrol-induced inhibitory effect on
cell migration was still evident when cells were pretreated
with resveratrol followed by EGF or E2. The demonstrated
inhibitory effect of resveratrol on directed cell migration is
also substantiated by previous studies, which reported that
resveratrol blocked the wound healing response of epithelial
cells [33,34] and invasion of phorbol myristate acetate–
induced cervical cancer cell invasion [36]. This inhibitory
effect of resveratrol on directed cell migration could be
accounted for by its reported antiproliferative and proapo-
ptotic properties. However, the short exposure times of our
experiments (10 minutes for detection of filopodia and focal
adhesion assembly and 8 hours for migration) makes this
possibility highly unlikely. We have examined the cells (by
propidium iodide staining of nuclei) at the end of our experi-
ments and they appear to be viable. Previous reports on the
role of resveratrol in apoptosis, where the authors incubated
cells for over 24 hours in micromolar concentrations of
resveratrol, support our inference that we are monitoring
rapid signaling effects and not effects of resveratrol on cell
growth [31,53–56].
In fibroblast-like cells such as MDA-MB-231 breast can-
cer cells, directed motility in response to a chemoattractant is
driven by cell polarization, polymerization of actin, and
incorporation of cross-linked actin filaments into leading-
edge lamellipodia and filopodia that are stabilized by making
focal adhesions with the ECM [39,57]. Lamellipodia are
considered to be essential for directed cell migration, where-
as filopodia are not essential for cell migration but considered
to serve as environmental sensors. Filopodia are often
reorganized to form leading-edge lamellipodia during cell
migration [39]. Thus, the observed cytoskeletal response to
resveratrol—where cells appear relatively unpolarized and
extend large numbers of unorganized peripheral filopodia
that are not associated with focal adhesions and do not get
converted to lamellipodia—is hypothesized to be directly
responsible for the inhibition of cell migration by resveratrol.
FAK is one of the first signaling intermediates recruited
to nascent focal adhesions. FAK-mediated increases in cell
proliferation, motility, and invasion have been correlated
with tumor malignancy [41,58]. Therefore, the observed re-
duced FAK activity in response to resveratrol at concen-
trations of 25 mM and above may also contribute to the
inhibitory effect of resveratrol on cell migration. This result
coincides with our reported decrease of focal adhesion
number with resveratrol at 50 mM. Reduction in focal con-
tacts with the ECM is known to activate apoptosis [58]; thus,
the resveratrol-mediated decreased FAK activity and focal
adhesion number may represent another pathway by which
resveratrol can induce apoptosis.
Rapid E2 effects have been shown to be mediated
through EGFR signaling [11]. EGFR activity is known to
regulate pathways leading to actin reorganization by non-
genomic mechanisms [50]. EGFR signaling activates the
Rho family GTPases, Rac and Cdc42, that regulate exten-
sion of cell surface actin structures such as filopodia and
lamellipodia [38,59]. Our results show that E2 acts similarly to
EGF and activates EGFR, increases directed cell migration,
lamellipodia extension, and focal adhesion assembly. Thus,
E2 and EGF may promote directed cell migration by similar
mechanisms that involve extension of lamellipodia with
multiple dynamic focal adhesions that support protrusion
and traction at the cell front during motility. Recent data have
demonstrated that EGF-induced filopodia are always asso-
ciated with basal focal adhesions and the filopodia that
contain shaft adhesions (focal adhesions inside the filopodia)
are useful for directed motility by conversion into lamellipodia
Figure 6. Effect of tyrphostin AG1478 on focal adhesion assembly in MDA-MB-231 cells. Cells were serum-starved in phenol red– free media for 24 hours and
pretreated with vehicle (AG1478) or tyrphostin AG1478 (+AG1478) for 15 minutes then treated with DMSO as control (Un), 0.1 M E2 (E2), 50 ng/ml EGF (EGF),
or 50 M trans-resveratrol (Res) for 10 minutes. Cells were probed with an anti-phosphotyrosine antibody followed by FITC secondary antibody to visualize focal
adhesions. Focal adhesion number was quantified for at least 10 microscopic fields per treatment per experiment and made relative to DMSO control (Un). Data
expressed as mean focal adhesions ± SEM of three independent experiments. Treatments denoted by the same letter indicate no significant difference between
those treatments. Treatments denoted by different letters indicate a significant difference between those treatments at P < .05.
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[60]. Interestingly, the filopodia extended in response to
resveratrol were not associated with basal or shaft adhe-
sions. Thus, the filopodia and focal adhesions assembled in
resveratrol-treated cells may be structurally and functionally
different from those assembled in response to E2 or EGF.
The effects of E2 and resveratrol on the cytoskeleton were
only evident in cells that expressed a functional ER isoform
and not in the ERab() SKRB3 cell line. When ERb(+) MDA-
MB-231 breast cancer cells were preincubated in resveratrol
and subsequently treated with E2, the cytoskeletal response
of increased filopodia and decreased focal adhesions was
similar to that of resveratrol alone, indicating that resveratrol
probably exerts its effects on the actin cytoskeleton through
ER. The slightly reduced cytoskeletal response of resveratrol
combined with E2, when compared to resveratrol alone, may
be due to the lower binding affinity of resveratrol for ERb
compared to E2 [61]. However, resveratrol has been shown
to exert potentially ER-independent effects on modulation of
enzymes such as cyclooxygenases and PKC isoforms
[25,26]. Thus, some of the effects of resveratrol on the actin
cytoskeleton may indicate an ER-independent alternate
pathway that blocks or overpasses ER action.
To investigate the potential role of EGFR signaling on
resveratrol and E2 effects on the cytoskeleton, we evaluated
the effect of inhibiting the kinase activity of EGFR1 with
tyrphostin AG1478. As expected, we observed an AG1478-
sensitive EGFR phosphorylation response to both E2 and
EGF. We also observed a reduction in lamellipodia and the
number of focal adhesions assembled in response to EGF or
E2 in the presence of AG1478. According to recent reports,
E2 acts through G proteins to activate EGFR-mediated
signaling to MAPK and Akt activity pathways that regu-
late cell proliferation and survival [11,15,62]. The present
study has elucidated a novel role for E2 in rapid signaling to
the actin cytoskeleton to promote directed migration that
may represent another relevant E2/EGFR–mediated signal-
ing pathway.
When cells were treated with resveratrol prior to EGF,
resveratrol did not directly interfere with EGF for signaling
to EGFR to exert effects on the cytoskeleton. However,
Figure 7. Effect of resveratrol on FAK activity in MDA-MB-231 cells. Cells were starved for 24 hours in phenol red– and serum-free media and treated with DMSO
as vehicle (0) or resveratrol (1, 10, 25, 50, or 100 M) for 10 minutes. (a) Equal amounts of protein were run on SDS-PAGE and Western-blotted using FAK
(N-terminus) or phosphoFAK (tyr-397) antibodies. (b) The integrated density of phosphoFAK and FAK bands from Western blots was quantified. Relative activity is
the difference between the ratio of phosphoFAK to total FAK with stimulation, and the ratio of phosphoFAK to FAK without stimulation. The result is representative
of three separate experiments.
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addition of AG1478 inhibited a portion of the filopodia ex-
tended in response to resveratrol. Thus, at least some of the
resveratrol-mediated effects on the actin cytoskeleton are
regulated by EGFR signaling. It is also possible that the
filopodia extended by resveratrol in the presence of AG1478
may still be under EGFR regulation because resveratrol-
induced autophosphorylation of EGFR could not be inhibited
by AG1478. This interesting result may be due to an
AG1478- insensitive resveratrol-mediated EGFR activation.
This possibility is substantiated by a recent report that
demonstrates an AG1478-independent activation of EGFR
phosphorylation through Src activity [63].
Interestingly, treatment of unstimulated cells with AG1478
(Un+) resulted in a significant increase in the number of
filopodia when compared to unstimulated control (Un). This
implies that EGFR activity was necessary to prevent filopo-
dia formation on unstimulated cells (Un). Moreover, when
E2- or EGF-treated cells were pretreated with AG1478, there
was also a significant increase in filopodia formation com-
pared to E2 or EGF alone. These perplexing results may be
explained if EGFR activity is important for the conversion of
filopodia into lamellipodia, as previously reported [64]. In our
microscopy studies, we have observed that when MDA-MB-
231 cells were stimulated with EGF, they responded initially
(at 5 minutes) by filopodia extension. These filopodia then
merged into lamellipodia, which were completely formed by
10 minutes. Based on this observation, it is possible that
AG1478-sensitive EGFR signaling is important for the con-
version of filopodia to lamellipodia, which may be regulated
by EGF or E2 through EGFR1 signaling. Thus, in the
presence of AG1478, the fraction of filopodia induced by
AG1478-insensitive alternate EGFR signaling may remain
as filopodia instead of reorganizing into lamellipodia.
The present study makes a significant contribution to the
field of nongenomic signaling of E2 and related compounds
by investigation of a novel role for E2 and resveratrol in
cancer cell migration through rapid reorganization of the
actin cytoskeleton. For the first time, we demonstrate that
resveratrol inhibits cell migration in response to E2 or EGF.
This inhibitory effect of resveratrol on cell migration may be
due to rapid filopodia formation without accompanying cell
polarization or attachment to the ECM. Taken together,
these findings indicate that resveratrol may have the poten-
tial to play a preventive role in the progression of ERa()
ERb(+) metastatic breast cancers that express EGFR. A
growing body of literature suggests that moderate red wine
consumption may have several health benefits, including a
lowered risk of breast cancer. The data presented implicate
an additional beneficial role for resveratrol in the prevention
of breast cancer cell invasion and metastasis.
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